NNVC icon

NanoViricides

1.35 USD
+0.06
4.65%
At close Feb 14, 4:00 PM EST
After hours
1.40
+0.05
3.70%
1 day
4.65%
5 days
12.50%
1 month
14.41%
3 months
0.75%
6 months
-29.32%
Year to date
-4.93%
1 year
15.38%
5 years
-81.61%
10 years
-97.72%
 

About: Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.

Employees: 7

0
Funds holding %
of 6,831 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

113% more call options, than puts

Call options by funds: $49K | Put options by funds: $23K

20% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 5

0.07% less ownership

Funds ownership: 11.41% [Q2] → 11.34% (-0.07%) [Q3]

9% less funds holding

Funds holding: 34 [Q2] → 31 (-3) [Q3]

13% less capital invested

Capital invested by funds: $2.32M [Q2] → $2.01M (-$308K) [Q3]

20% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 5

Research analyst outlook

We haven’t received any recent analyst ratings for NNVC.

Financial journalist opinion

Based on 7 articles about NNVC published over the past 30 days

Positive
Proactive Investors
3 days ago
NanoViricides announces readiness to combat bird flu with antiviral drug NV-387
NanoViricides (NYSE-A:NNVC) stated today that it is prepared to address the escalating threat of bird flu with its broad-spectrum antiviral drug, NV-387. The company asserts that NV-387 is designed to remain effective against the H5N1 virus, even as the virus undergoes rapid mutations.
NanoViricides announces readiness to combat bird flu with antiviral drug NV-387
Neutral
Accesswire
3 days ago
NanoViricides Drug Can Fight Bird Flu Pandemic; H5N1 Virus Cannot Escape
SHELTON, CT / ACCESS Newswire / February 11, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") declared today that it is ready to fight the bird flu with its revolutionary broad-spectrum antiviral drug NV-387, a drug that the Bird Flu virus H5N1 likely cannot escape despite its ability to mutate rapidly with genomic changes.
NanoViricides Drug Can Fight Bird Flu Pandemic; H5N1 Virus Cannot Escape
Positive
Proactive Investors
1 week ago
NanoViricides seeks to eliminate treatment delays with its broad spectrum antiviral NV-387
With its broad-spectrum antiviral drug NV-387, NanoViricides (NYSE-A:NNVC) sees a future where patients with a range of viral diseases can access treatment as quickly as they can secure antibiotics for a bacterial infection.  “Today if a patient goes to the doctor with a viral infection, they are told to go home and relax.
NanoViricides seeks to eliminate treatment delays with its broad spectrum antiviral NV-387
Negative
Proactive Investors
2 weeks ago
NanoViricides warns of bird flu pandemic as outbreak spreads in Massachusetts
Bird flu is likely widespread among birds in Massachusetts, State health and environmental officials said this week on Wednesday, as new cases are reported in both wild and domestic birds across multiple municipalities. Bird flu, or H5N1, is a type of highly pathogenic avian influenza that causes severe disease in birds and occasionally infects humans.
NanoViricides warns of bird flu pandemic as outbreak spreads in Massachusetts
Neutral
Accesswire
2 weeks ago
NanoViricides to Present at the MicroCap Conference on Wednesday, January 29, 2025
SHELTON, CT / ACCESS Newswire / January 29, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot escape, announced that it is presenting today, January 29, at 11am at the MicroCap Conference 2025 in Atlantic City, NJ. Event Information: Event NanoViricides Presentation at the MicroCap Conference, Atlantic City Day & Date Wednesday, January 29, 2025 Time 11:00 am to 11:30 am Location The Borgata Hotel, Atlantic City, NJ Admission Open Admission Policy, Everyone is Welcome NanoViricides is rapidly moving towards Phase II Safety, Tolerability and Efficacy Evaluation of its Lead Drug candidate, NV-387, for the Treatment of MPOX disease.
NanoViricides to Present at the MicroCap Conference on Wednesday, January 29, 2025
Positive
Proactive Investors
2 weeks ago
NanoViricides taps clinical research organization for Phase II trial of NV-387
NanoViricides (NYSE-A:NNVC) said on Monday it had engaged a clinical research organization to conduct a Phase II trial for its broad-spectrum antiviral drug NV-387. The Connecticut-based company is targeting NV-387 for the treatment of MPox, a disease caused by the human Mpox virus (hMPXV), which has spurred a regional pandemic in parts of Africa, including the Democratic Republic of Congo and Uganda.
NanoViricides taps clinical research organization for Phase II trial of NV-387
Neutral
Accesswire
2 weeks ago
NanoViricides Engages CRO for Phase II Clinical Trial
SHELTON, CT / ACCESS Newswire / January 27, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") today announced that it has engaged a Clinical Research Organization (CRO) to conduct a Phase II clinical trial advancing its broad-spectrum antiviral drug NV-387 further into the regulatory pipeline. "NV-387, our broad-spectrum antiviral drug is poised to cause a revolution in treatment of viral diseases, just as antibiotics revolutionized the treatment of bacterial diseases," said Anil R.
NanoViricides Engages CRO for Phase II Clinical Trial
Neutral
Accesswire
1 month ago
NanoViricides to Present at the Biotech Showcase in San Fransisco on Tuesday, January 14, 2025
SHELTON, CT / ACCESSWIRE / January 13, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot escape, announced today that it is presenting at Biotech Showcase™ 2025 in San Fransisco, being held in parallel to the JP Morgan Life Sciences Conference. Event Information: Event NanoViricides Presentation at the Biotech Showcase, San Fransisco Day & Date Tuesday, January 14, 2025 Time, Track & Room 2:30pm PT, Yosemite A (Ballroom Level) Location Hilton San Fransisco - Union Square Anil R.
NanoViricides to Present at the Biotech Showcase in San Fransisco on Tuesday, January 14, 2025
Positive
Proactive Investors
1 month ago
NanoViricides CEO discusses NV-387's broad spectrum promise - ICYMI
NanoViricides (NYSE-A:NNVC) CEO Dr Anil Diwan joined Proactive to highlight the company's lead drug candidate NV-387, which is targeting multiple viral families by mimicking receptors essential for viral infections. He highlighted that NV-387 has shown exceptional efficacy in preclinical studies, including curing RSV infections in animal models.
NanoViricides CEO discusses NV-387's broad spectrum promise - ICYMI
Positive
Proactive Investors
1 month ago
NanoViricides highlights urgent need for broad-spectrum antiviral solutions amid viral threats
NanoViricides (NYSE-A:NNVC) has highlighted the growing need for innovative antiviral solutions amid rising concerns over multiple viral threats, including H5N1 bird flu, COVID-19, RSV, and human metapneumovirus (hMPV). The company is advancing NV-387, a promising broad-spectrum antiviral candidate designed to target a wide range of rapidly mutating RNA viruses.
NanoViricides highlights urgent need for broad-spectrum antiviral solutions amid viral threats
Charts implemented using Lightweight Charts™